The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells
- PMID: 15761501
- PMCID: PMC1062891
- DOI: 10.1172/JCI22758
The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells
Retraction in
-
The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.J Clin Invest. 2016 Apr 1;126(4):1603. doi: 10.1172/JCI87345. Epub 2016 Apr 1. J Clin Invest. 2016. PMID: 27035814 Free PMC article. No abstract available.
Abstract
In papillary thyroid carcinomas (PTCs), rearrangements of the RET receptor (RET/PTC) and activating mutations in the BRAF or RAS oncogenes are mutually exclusive. Here we show that the 3 proteins function along a linear oncogenic signaling cascade in which RET/PTC induces RAS-dependent BRAF activation and RAS- and BRAF-dependent ERK activation. Adoptive activation of the RET/PTC-RAS-BRAF axis induced cell proliferation and Matrigel invasion of thyroid follicular cells. Gene expression profiling revealed that the 3 oncogenes activate a common transcriptional program in thyroid cells that includes upregulation of the CXCL1 and CXCL10 chemokines, which in turn stimulate proliferation and invasion. Thus, motile and mitogenic properties are intrinsic to transformed thyroid cells and are governed by an epistatic oncogenic signaling cascade.
Figures
Similar articles
-
BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.Endocrinology. 2006 Feb;147(2):1014-9. doi: 10.1210/en.2005-0280. Epub 2005 Oct 27. Endocrinology. 2006. PMID: 16254036
-
Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.J Clin Endocrinol Metab. 2012 Jun;97(6):E898-906. doi: 10.1210/jc.2011-3269. Epub 2012 Mar 22. J Clin Endocrinol Metab. 2012. PMID: 22442268
-
Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes.Oncogene. 2003 Jan 16;22(2):246-55. doi: 10.1038/sj.onc.1206112. Oncogene. 2003. PMID: 12527893
-
Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.Cancer. 2005 Jun 1;103(11):2261-8. doi: 10.1002/cncr.21073. Cancer. 2005. PMID: 15880523 Review.
-
[BRAF gene mutation in thyroid cancer].Pol Merkur Lekarski. 2006 Feb;20(116):210-3. Pol Merkur Lekarski. 2006. PMID: 16708643 Review. Polish.
Cited by
-
Autoimmune Thyroid Disease and Differentiated Thyroid Carcinoma: A Review of the Mechanisms That Explain an Intriguing and Exciting Relationship.World J Oncol. 2024 Feb;15(1):14-27. doi: 10.14740/wjon1728. Epub 2023 Dec 9. World J Oncol. 2024. PMID: 38274715 Free PMC article. Review.
-
Whether Detection of Gene Mutations Could Identify Low- or High-Risk Papillary Thyroid Microcarcinoma? Data from 393 Cases Using the Next-Generation Sequencing.Int J Endocrinol. 2024 Jan 16;2024:2470721. doi: 10.1155/2024/2470721. eCollection 2024. Int J Endocrinol. 2024. PMID: 38268989 Free PMC article.
-
IL-17 A correlates with disease progression in papillary thyroid carcinoma.Diagn Pathol. 2023 Aug 10;18(1):93. doi: 10.1186/s13000-023-01362-4. Diagn Pathol. 2023. PMID: 37563607 Free PMC article.
-
RET rearrangements are relevant to histopathologic subtypes and clinicopathological features in Thai papillary thyroid carcinoma patients.Pathol Oncol Res. 2023 Apr 28;29:1611138. doi: 10.3389/pore.2023.1611138. eCollection 2023. Pathol Oncol Res. 2023. PMID: 37188126 Free PMC article.
-
Identifying the Carcinogenic Mechanism of Malignant Struma Ovarii Using Whole-Exome Sequencing and DNA Methylation Analysis.Curr Issues Mol Biol. 2023 Feb 23;45(3):1843-1851. doi: 10.3390/cimb45030118. Curr Issues Mol Biol. 2023. PMID: 36975488 Free PMC article.
References
-
- Rosai, J., Carcangiu, M.L., and DeLellis, R.A. 1992. Atlas of tumor pathology: tumors of the thyroid gland. 3rd series. Armed Forces Institute of Pathology. Washington, D.C., USA. 343 pp.
-
- Manie S, Santoro M, Fusco A, Billaud M. The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet. 2001;17:580–589. - PubMed
-
- Fagin JA. Perspective: lessons learned from molecular genetic studies of thyroid cancer--insights into pathogenesis and tumor-specific therapeutic targets. Endocrinology. 2002;143:2025–2028. - PubMed
-
- Santoro M, et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene. 1996;12:1821–1826. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
